Latest / Community Health Media
Dr. Jason Mouabbi, Dr. Fenting Yan, & Dr. Paolo Tarantino - First-Line T-DXd in HER2+ mBC
Can T-DXd plus pertuzumab finally replace the CLEOPATRA regimen as the new first-line standard for metastatic HER2-positive breast cancer?
In this comprehensive discussion from ASCO 2026, Dr. Jason Mouabbi, Dr. Fengting Yan, and Dr. Paolo Tarantino break down the practice-changing DESTINY-Breast09 data and what it means for treatment sequencing, patient selection and toxicity management. Beyond the clinical trial results, the experts share their perspectives on the evolving therapeutic landscape—specifically, the future possibility of achieving cures in metastatic HER2-positive breast cancer…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.